Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LG-0317 SERT Occupancy Study in Healthy Participants
NCT07708428Phase 1Not yet recruiting
- Sponsor
- Lingang Laboratory
- Start
- Jul 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, open-label trial of LG-0317 in major depressive disorder (MDD) (3 cohorts), sponsored by Lingang Laboratory. Primary endpoint: Serotonin Transporter Occupancy at Day 1. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
LG-0317
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07708428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708428.